HeartSciences Inc. (NASDAQ:HSCS) Sees Significant Increase in Short Interest

HeartSciences Inc. (NASDAQ:HSCS) was the recipient of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 75,969 shares, a growth of 160.9% from the December 15th total of 29,118 shares. Currently, 2.4% of the shares of the company are short sold. Based on an average daily trading volume, of 73,534 shares, the short-interest ratio is presently 1.0 days. Based on an average daily trading volume, of 73,534 shares, the short-interest ratio is presently 1.0 days. Currently, 2.4% of the shares of the company are short sold.

Institutional Investors Weigh In On HeartSciences

A hedge fund recently bought a new stake in HeartSciences stock. Geode Capital Management LLC bought a new position in shares of HeartSciences Inc. (NASDAQ:HSCS) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 11,599 shares of the company’s stock, valued at approximately $43,000. Geode Capital Management LLC owned about 0.51% of HeartSciences as of its most recent SEC filing. Institutional investors own 17.24% of the company’s stock.

HeartSciences Trading Up 1.3%

NASDAQ:HSCS traded up $0.04 on Thursday, hitting $3.20. The company had a trading volume of 41,683 shares, compared to its average volume of 49,752. HeartSciences has a 52 week low of $2.01 and a 52 week high of $6.47. The stock has a market capitalization of $10.18 million, a price-to-earnings ratio of -0.47 and a beta of 2.52. The firm has a 50 day moving average of $2.79 and a two-hundred day moving average of $3.29.

HeartSciences (NASDAQ:HSCS) last issued its quarterly earnings data on Monday, December 15th. The company reported ($0.85) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.05. The firm had revenue of $2.42 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, equities analysts forecast that HeartSciences will post -10.01 EPS for the current year.

Analyst Upgrades and Downgrades

HSCS has been the topic of a number of recent research reports. Ascendiant Capital Markets increased their price target on HeartSciences from $9.00 to $9.20 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Weiss Ratings reissued a “sell (e+)” rating on shares of HeartSciences in a report on Monday, December 29th. Finally, Wall Street Zen raised HeartSciences from a “sell” rating to a “hold” rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $9.20.

About HeartSciences

HeartSciences, Inc (NASDAQ: HSCS) is a medical device company focused on the development and commercialization of advanced, non‐invasive cardiac diagnostic technologies. The company’s flagship product, MyoVista, is a high‐fidelity electrocardiograph (ECG) designed to detect subtle changes in cardiac function that may indicate myocardial ischemia or left ventricular dysfunction. By leveraging high‐frequency wavelet analysis within the QRS complex, MyoVista provides clinicians with enhanced visualization and analytical capabilities that extend beyond those of standard ECG systems.

HeartSciences supports the MyoVista system with an integrated software suite that automates data analysis and report generation, facilitating seamless integration into existing clinical workflows.